삼성에피스홀딩스

0126Z0KOSPI

53.0 / 100

Reference Date: 2026-09-08

Financial Score19.0 / 40

News Sentiment19.0 / 25

Momentum8.0 / 20

Disclosure7.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 12.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Samsung Epis Holdings is a biotech investment holding company with two subsidiaries, Samsung Bioepis and Epis Nex Lab. Samsung Bioepis focuses on commercializing 11 biosimilar products, contributing 96.7% of 2025 revenue, and is expanding into ADC drug development. Epis Nex Lab, established in 2025, is focused on next-generation biotech platforms but has not yet generated revenue.

Number of Employees

18people

Average Salary

—

Score Calculation Basis

Detailed Financial Score

PER

104.86Industry Average 15.000.0Point

7.0x industry avg (risky)

PBR

1.52Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

—Industry Average 8.003.5Point

Debt Ratio

6.92Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 5.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

2.0 / 4

Detailed News Sentiment

11 totalPositive 8Neutral 2Negative 1Average Sentiment Score 75.9

Positive
[K바이오 돈의 경로] 분할 뒤 성장투자축 이원화｜삼성바이오①
삼성에피스홀딩스의 인적분할로 인해 성장 자금이 CDMO와 바이오시밀러 분야에 집중 투자되어 사업 다각화와 수익 증대가 기대된다.
Neutral
[오너 자본방정식] 삼성물산·제일모직 합병 11년…이재용 회장이 얻.....
The news discusses long-term implications of corporate capital transactions but does not directly impact Samsung Episco Holdings' stock performance.
Positive
[바이오사 리포트] 삼성에피스, 바이오젠 추가 지급부담 사실상 '제로....
삼성에피스홀딩스는 바이오젠과의 계약 재조정으로 추가 인수대금 부담이 크게 줄어들어 재무 부담이 크게 감소했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 360,000Won52-week high 743,00052-week low 335,500

1-month return1.0Point

1m -12.52% (falling)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

5 totalPositive 0Neutral 4Negative 1

Neutral최대주주등소유주식변동신고서2026-09-07
Neutral대규모기업집단현황공시[분기별공시(개별회사용)]2026-08-31
Negative지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항2026-08-14
Neutral반기보고서 (2026.06)2026-08-14
Neutral투자판단관련주요경영사항(자회사의 주요경영사항) (SB27주(펨브롤리주맙 바이오시밀러) 한국 품목허가 신청)2026-08-10